---
schema_version: "secwatch.filing_event.v1"
accession: "0001370053-22-000017"
form_type: "8-K"
ticker: "ANAB"
cik: "0001370053"
company_name: "ANAPTYSBIO, INC"
filed_at: "2022-03-21T23:59:59+00:00"
generated_at: "2026-06-26T21:19:07.109402+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# AnaptysBio CEO Hamza Suria resigns; Daniel Faga named Interim President and CEO

## Summary
- Hamza Suria resigned as President, CEO and Class II director effective March 20, 2022.
- Suria receives $603,580 salary continuation for 12 months and COBRA reimbursement; consulting through March 2023.
- Daniel Faga, former Mirati COO and Spark CBO, appointed Interim CEO effective March 21, 2022.
- Faga receives base salary $603,580, 55% target bonus, and 887,043 RSUs vesting over 24 months.
- Faga's RSU vests fully on change of control termination or if new CEO hired; severance includes 12 months salary.

## SEC filing metadata
- accession: 0001370053-22-000017
- form_type: 8-K
- ticker: ANAB
- cik: 0001370053
- company_name: ANAPTYSBIO, INC
- filed_at: 2022-03-21T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1370053/000137005322000017/0001370053-22-000017-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1370053/000137005322000017/anab-20220320.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001370053-22-000017
- JSON: https://secwatch.observer/filing/0001370053-22-000017.json
- Plain text: https://secwatch.observer/filing/0001370053-22-000017.txt

## Key facts
- Executive change
  Daniel Faga was appointed as Interim President and Chief Executive Officer at ANAPTYSBIO, INC.
  - Action: appointed
  - Role: Interim President and Chief Executive Officer
  source text: the Company appointed Daniel Faga, a Class I director of the Board, to serve as Interim President and Chief Executive Officer of the Company, effective as of March 21, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1370053/000137005322000017/0001370053-22-000017-index.htm
- Executive change
  Hamza Suria resigned as President and Chief Executive Officer at ANAPTYSBIO, INC.
  - Action: resigned
  - Role: President and Chief Executive Officer
  source text: On March 20, 2022, Hamza Suria, provided notice to the board of directors (the “Board”) of AnaptysBio, Inc. (the “Company”) of his resignation as President and Chief Executive Officer and as a Class II director of the Company, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1370053/000137005322000017/0001370053-22-000017-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.